Bio-Rad Laboratories, Inc. (NYSE:BIO) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $225.00.

BIO has been the subject of several recent analyst reports. Zacks Investment Research raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price objective for the company in a report on Monday, May 1st. BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and set a $250.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, April 11th. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective for the company. Finally, Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price objective for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/07/bio-rad-laboratories-inc-nysebio-receives-consensus-recommendation-of-buy-from-brokerages.html.

Shares of Bio-Rad Laboratories (NYSE:BIO) opened at 227.31 on Monday. The company’s 50-day moving average is $228.57 and its 200 day moving average is $210.72. Bio-Rad Laboratories has a 52-week low of $143.39 and a 52-week high of $239.91. The company has a market cap of $6.73 billion, a PE ratio of 241.31 and a beta of 0.91.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.14. The business had revenue of $500.05 million during the quarter, compared to analyst estimates of $477.76 million. Bio-Rad Laboratories had a return on equity of 3.23% and a net margin of 1.35%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.42 EPS. On average, analysts anticipate that Bio-Rad Laboratories will post $2.94 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board purchased a new stake in Bio-Rad Laboratories during the second quarter worth $113,000. Advisory Services Network LLC purchased a new stake in Bio-Rad Laboratories during the first quarter worth $115,000. Flinton Capital Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after buying an additional 96 shares during the last quarter. Turner Investments LLC purchased a new stake in Bio-Rad Laboratories during the second quarter worth $136,000. Finally, Meadow Creek Investment Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Meadow Creek Investment Management LLC now owns 880 shares of the medical research company’s stock worth $175,000 after buying an additional 132 shares during the last quarter. Institutional investors own 63.70% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.